News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 

New Anti-Depressant Drug Funded

Media release

New Anti-Depressant Drug Funded

A new treatment for depression will be funded from 1 January 2004 following an agreement between PHARMAC and pharmaceutical company Wyeth (NZ) Ltd.

Venlafaxine (Efexor XR) will be listed on the Pharmaceutical Schedule for the treatment of severe depression, and can be used both in hospitals and in community settings.

PHARMAC medical director Dr Peter Moodie says funding venlafaxine will give clinicians another valuable tool to help people whose depression has proved difficult to treat.

“Venlafaxine is an effective treatment for those people who have not responded to other antidepressants, so it is pleasing to be able to provide fully-funded access to it,” says Dr Moodie.

“We are aware that clinicians have been asking to have this drug available for patients, so its benefits are already recognised. The clinical advice PHARMAC has received has also been positive so we are happy to have reached an agreement with Wyeth that has allowed it to be funded.”

PHARMAC is anticipating that just under $1 million will be spent subsidising venlafaxine in the first year, rising to about $5 million after five years. Patient numbers are difficult to estimate, but could be up to 8000, Dr Moodie says.

Since Venlafaxine exhibits inhibition of serotonin and noradrenaline uptake it may be useful in those patients who failed to respond to SSRIs or other antidepressants, Dr Moodie says.

Dr Moodie says this listing also assists in meeting the Government’s commitment to improving mental health services, as outlined in the New Zealand Health Strategy.

[ends]

© Scoop Media

 
 
 
Culture Headlines | Health Headlines | Education Headlines

 


Howard Davis: Off The Hidden Path - Five Los Angeles Treasures (Part I)

The immense cultural diversity of LA provides an extraordinary variety of lifestyles and arhcitecture. Here are five 'hidden' destinations where the discerning traveller can appreciate and enjoy this unique and constantly evolving metropolis. More>>


City Of 100 Lovers: Multi-Million Dollar NZ Theatre Production To Launch

Produced in New Zealand with an $8 million budget, this musical comedy has been created with both locals and tourists in mind. More>>


Howard Davis Review: The Outsider Art of Tony Fomison

Among such gifted contemporaries as Bill Hammond, Tony de la Tour, and printmaker Jason Grieg, Fomison distinguished himself as highly idiosyncratic, and could have become wealthy, had not his demons prevented him from investing his income wisely. In his near monochrome oil painting on black hessian, he staked out a territory of morbid originality. More>>

Scoop Review Of Books: Immortal Love

The series has a wild-west tone with a steampunk vibe, so if you’re a fan of Joss Whedon’s Firefly or Joe Abercrombie’s Shattered Sea, then chances are you’ll enjoy this book. More>>

Howard Davis Review: The Trappings of Success - McQueen

This troubling documentary about the extraordinary life and untimely death of British fashion designer Alexander McQueen is a cautionary tale of an extremely gifted, but self-destructive soul caught up in a business that chews up and spits out its creative talent. More>>

Indycars: Dixon Wins Fifth US Championship

The New Zealand motor racing driver Scott Dixon has won the US Indycar championship for the fifth time, finishing second in the final race of the season in Sonoma, California. More>>

ALSO:

 
 
 
 
 

LATEST HEADLINES

  • CULTURE
  • HEALTH
  • EDUCATION
 
 
  • Wellington
  • Christchurch
  • Auckland